Mixture-of-exponentials models to explain heterogeneity in studies of the duration of Chlamydia trachomatis infection

Statistics in Medicine

Volumn 32, Issue 9, 2013, Pages 1547-1560

  Price, Malcolm J ^a   Ades, A E ^a   Angelis, Daniela De ^b,c   Welton, Nicky J ^a   Macleod, John ^a   Soldan, Kate ^b   Turner, Katy ^a   Simms, Ian ^b   Horner, Paddy J ^a,d  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c MRC BIOSTATISTICS UNIT   (United Kingdom)

^d UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Bayesian; Chlamydia trachomatis; Duration of infection; Evidence synthesis; Heterogeneity; Mixture of exponentials

Indexed keywords

ARTICLE; BACTERIAL CLEARANCE; BAYES THEOREM; CHLAMYDIASIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE DURATION; FAST CLEARING INFECTION; FEMALE; FIRST CLASS MIXTURE OF EXPONENTIAL MODEL; HUMAN; INFECTION; INFECTION RATE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MIXTURE OF EXPONENTIAL MODEL; PASSIVE INFECTION; PROBABILITY; RANDOM EFFECT MODEL; SINGLE FIXED EFFECT CLEARANCE RATE MODEL; SLOW CLEARING INFECTION; STATISTICAL ANALYSIS; STATISTICAL MODEL; THREE CLASS MIXTURE OF EXPONENTIAL MODEL; TWO CLASS MIXTURE OF EXPONENTIAL MODEL;

BAYES THEOREM; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; FEMALE; HUMANS; INCIDENCE; MARKOV CHAINS; MODELS, IMMUNOLOGICAL; MODELS, STATISTICAL; MONTE CARLO METHOD; PREVALENCE;

EID: 84876342168     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5603     Document Type: Article

References (54)

1. Roberts TE, Robinson S, Barton PM, Bryan S, McCarthy A, Macleod J, Egger M, Low N. Cost effectiveness of home based population screening for Chlamydia trachomatis in the UK: economic evaluation of chlamydia screening studies (ClaSS) project. British Medical Journal 2007; 335:291-294A. DOI: 10.1136/bmj.39262.683345.AE.
2. Turner KME, Adams EJ, LaMontagne DS, Emmett L, Baster K, Edmunds WJ. Modelling the effectiveness of chlamydia screening in England. Sexually Transmitted Infections 2006; 82:496-502. DOI: 10.1136/sti.2005.019067.
3. Kretzschmar M, vanDuynhoven YTHP, Severijnen AJ. Modeling prevention strategies for gonorrhea and chlamydia using stochastic network simulations. American Journal of Epidemiology, AM 1996; 144:306-317.
4. Turner KME, Adams EJ, Gay N, Ghani AC, Mercer C, Edmunds WJ. Developing a realistic sexual network model of chlamydia transmission in Britain. Theoretical Biology and Medical Modelling 2006; 3:3. DOI: 10.1186/1742-4682-3-3.
5. Golden MR, Schillinger JA, Markowitz L, St Louis ME. Duration of untreated genital infections with Chlamydia trachomatis-a review of the literature. Sexually Transmitted Diseases 2000; 27:329-337. DOI: 10.1097/00007435-200007000-00006.
6. Geisler WM. Duration of untreated, uncomplicated Chlamydia trachomatis genital infection and factors associated with chlamydia resolution: a review of human studies. Journal of Infectious Diseases 2010; 201(Suppl 2):S104-S113. DOI: 10.1086/652402.
7. Korenromp EL, Sudaryo MK, de Vlas SJ, Gray RH, Sewankambo NK, Serwadda D, Wawer MJ, Habbema JDF. What proportion of episodes of gonorrhoea and chlamydia becomes symptomatic? International Journal of STD & AIDS 2002; 13:91-101.
8. Kretzschmar M, Welte R, Van den Hoek A, Postma MJ. Comparative model-based analysis of screening programs for Chlamydia trachomatis infections. American Journal of Epidemiology, AM 2001; 153:90-101. DOI: 10.1258/0956462021924712.
9. Rahm VA, Belsheim J, Gleerup A, Gnarpe H, Rosen G. Asymptomatic carriage of Chlamydia-trachomatis-a study of 109 teenage girls. European Journal of Sexually Transmitted Diseases 1986; 3:91-94.
10. Althaus C, Heijne J, Roellin A, Low N. Transmission dynamics of Chlamydia trachomatis affect the impact of screening programs. Epidemics 2010; 2:123-131.
11. Jewell NP. Mixtures of exponential-distributions. Annals of Statistics 1982; 10:479-484. DOI: 10.1214/aos/1176345789.
12. Adams EJ, Turner KME, Edmunds WJ. The cost effectiveness of opportunistic chlamydia screening in England. Sexually Transmitted Infections 2007; 83:267-274. DOI: 10.1136/sti.2006.024364.
13. Ginocchio RHS, Veenstra DL, Connell FA, Marrazzo JM. The clinical and economic consequences of screening young men for genital chlamydial infection. Sexually Transmitted Diseases 2003; 30:99-106. DOI: 10.1097/00007435-200302000-00001.
14. Goeree R, Jang D, Blackhouse G, Chong S, Mahony J, Sellors J, Foy A, Chernesky M. Cost-effectiveness of screening swab or urine specimens for Chlamydia trachomatis from young Canadian women in Ontario. Sexually Transmitted Diseases 2001; 28:701-709. DOI: 10.1097/00007435-200112000-00007.
15. Hu D, Hook EW, Goldie SJ. Screening for Chlamydia trachomatis in women 15 to 29years of age: a cost-effectiveness analysis. Annals of Internal Medicine 2004; 141:501-513.
16. Mehta SD, Bishai D, Howell R, Rothman RE, Quinn TC, Zenilman JM. Cost-effectiveness of five strategies for gonorrhea and chlamydia control among female and male emergency department patients. Sexually Transmitted Diseases 2002; 29:83-91. DOI: 10.1097/00007435-200202000-00004.
17. Townshend JRP, Turner HS. Analysing the effectiveness of chlamydia screening. Journal of the Operational Research Society 2000; 51:812-824. DOI: 10.1057/palgrave.jors.2600978.
18. Wang LY, Burstein GR, Cohen DA. An economic evaluation of a school-based sexually transmitted disease screening program. Sexually Transmitted Diseases 2002; 29:737-745. DOI: 10.1097/00007435-200212000-00001.
19. Welte R, Kretzschmar M, Leidl R, Van den Hoek A, Jager JC, Postma MJ. Cost-effectiveness of screening programs for Chlamydia trachomatis-a population-based dynamic approach. Sexually Transmitted Diseases 2000; 27:518-529. DOI: 10.1097/00007435-200010000-00005.
20. Gottlieb SL, Martin DH, Xu FJ, Byrne GI, Brunham RC. Summary: the natural history and immunobiology of Chlamydia trachomatis genital infection and implications for chlamydia control. Journal of Infectious Diseases 2010; 202:S190-S204. DOI: 10.1086/652401.
21. Rogers SM, Miller WC, Turner CF, Ellen J, Zenilman J, Rothman R, Villarroel MA, Al-Tayyib A, Leone P, Gaydos C, Ganapathi L, Hobbs M, Kanouse D. Concordance of Chlamydia trachomatis infections within sexual partnerships. Sexually Transmitted Infections 2008; 84:23-28. DOI: 10.1136/sti.2007.027029.
22. Parks KS, Dixon PB, Richey CM, Hook EW. Spontaneous clearance of Chlamydia trachomatis infection in untreated patients. Sexually Transmitted Diseases 1997; 24:229-235. DOI: 10.1097/00007435-199704000-00008.
23. Schachter J, Hanna L, Hill EC, Massad S, Sheppard CW, Conte JE, Cohen SN, Meyer KF. Chlamydial infections most prevalent venereal-disease. Journal of the American Medical Association 1975; 231:1252-1255. DOI: 10.1001/jama.231.12.1252.
24. Tsukagoshi T. Epidemiological study on Chlamydia trachomatis infection among sexually active female adolescents. Acta Obstetrica et Gynaecologica Japonica (Japanese Edition) 1990; 42:1655-1662.
25. van Valkengoed IGM, Morre SA, van den Brule AJ, Meijer CJ, Bouter LM, van Eijk JT, Boeke AJ. Follow-up, treatment, and reinfection rates among asymptomatic Chlamydia trachomatis cases in general practice. British Journal of General Practice 2002; 52:623-627.
26. Molano M, Meijer CJLM, Weiderpass E, Arslan A, Posso H, Franceschi S, Ronderos M, Munoz N, van den Brule AJC. The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. Journal of Infectious Diseases 2005; 191:907-916. DOI: 10.1086/428287.
27. Morre SA, van den Brule AJC, Rozendaal L, Boeke AJP, Voorhorst FJ, de Blok S, Meijer CJLM. The natural course of asymptomatic Chlamydia trachomatis infections: 45% clearance and no development of clinical PID after one-year follow-up. International Journal of STD & AIDS 2002; 13:12-18. DOI: 10.1258/095646202762226092.
28. Johannisson G, Lowhagen GB, Lycke E. Genital Chlamydia trachomatis infection in women. Obstetrics and Gynecology 1980; 56:671-675.
29. Joyner JL, Douglas JM, Foster M, Judson FN. Persistence of Chlamydia trachomatis infection detected by polymerase chain reaction in untreated patients. Sexually Transmitted Diseases 2002; 29:196-200. DOI: 10.1097/00007435-200204000-00002.
30. Geisler WM, Wang C, Morrison SG, Black CM, Bandea CI, Hook EW. The natural history of untreated Chlamydia trachomatis infection in the interval between screening and returning for treatment. Sexually Transmitted Diseases 2008; 35:119-123. DOI: 10.1097/OLQ.0b013e318151497d.
31. Paavonen J, Kousa M, Saikku P, Vartiainen E, Kanerva L, Lassus A. Treatment of non-gonococcal urethritis with trimethoprim-sulfadiazine and with placebo-a double-blind partner-controlled study. British Journal of Venereal Diseases 1980; 56:101-104.
32. Sorensen JL, Thranov I, Hoff G, Dirach J. Early-onset and late-onset pelvic-inflammatory-disease among women with cervical Chlamydia trachomatis infection at the time of induced-abortion-a follow-up-study. Infection 1994; 22:242-246. DOI: 10.1007/BF01739907.
33. Mccormack WM, Alpert S, Mccomb DE, Nichols RL, Semine DZ, Zinner SH. 15-Month follow-up-study of women infected with Chlamydia trachomatis. New England Journal of Medicine 1979; 300:123-125. DOI: 10.1056/NEJM197901183000305.
34. Sheffield JS, Andrews WW, Klebanoff MA, MacPherson C, Carey PC, Ernest JM, Wapner RJ, Trout W, Moawad A, Miodovnik M, Sibai B, Varner MW, Caritis SN, Dombrowski M, Langer O, O'Sullivan MJ. Spontaneous resolution of asymptomatic Chlamydia trachomatis in pregnancy. Obstetrics and Gynecology 2005; 105:557-562. DOI: 10.1097/01.AOG.0000153533.13658.c2.
35. Alexander ER, Chandler J, Pheifer TA, Wang S-P, English M, Holmes KK. Prospective study of peri natal Chlamydia trachomatis infection. In Nongonococcal Urethritis and Related Infections Workshop, Lake Placid, NY, USA, 28-30 April 1976, Hobson D, Holmes KK (eds). American Society for Microbiology: Washington, DC, USA, 1977; 148-152. xvi + 391p illus, ISBN: 0-914826-11-5.
36. McCullagh P, Nelder JA.Generalised Linear Models. Chapman and Hall: London, 1989.
37. Zelen M, Feinleib M. On theory of screening for chronic diseases. Biometrika 1969; 56:601-614.
38. Spiegelhalter D, Thomas A, Best N, Lunn D.WinBUGS user manual version 1.4, January 2003, upgraded to version 1.4.3, 2007. (Available from: http://www.mrc-bsu.com.ac.uk/bugs [Accessed on August 2012]).
39. Eddy DM, Hasselblad V, Shachter R.Meta-analysis by the Confidence Profile Method. Academic Press: London, 1992.
40. Brooks SP, Gelman A. Alternative methods for monitoring convergence of iterative simulations. Journal of Computational and Graphical Statistics 1998; 7:434-455.
41. Spiegelhalter DJ, Best N, Carlin BP. Bayesian deviance: the effective number of parameters, and the comparison of arbitrarily complex models. Research Report 98-009, Division of Biostatistics, University of Minnesota, 1998.
42. Dempster AP. The direct use of likelihood for significance testing. Statistics and Computing 1997; 7:247-252. DOI: 10.1023/A:1018598421607.
43. Welton NJ, Ades AE. A model of toxoplasmosis incidence in the UK: evidence synthesis and consistency of evidence. Journal of the Royal Statistical Society Series C-Applied Statistics 2005; 54:385-404. DOI: 10.1111/j.1467-9876.2005.00490.x.
44. Jamieson DJ, Theiler RN, Rasmussen SA. Emerging infections and pregnancy. Emerging Infectious Diseases 2006; 12:1638-1643. DOI: 10.1023/A:1018598421607.
45. Brunham RC, Rey-Ladino J. Immunology of chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nature Reviews Immunology 2005; 5:149-161. DOI: 10.1038/nri1551.
46. Mallinson H, Hopwood J, Mutton K. Resolution of the recent performance problem of Abbott LCx Chlamydia trachomatis assay. Issues of repeat testing for confirmation of chlamydial infection. Sexually Transmitted Infections 2002; 78:225-226. DOI: 10.1136/sti.78.3.225-a.
47. Ward M.Molecular diagnostics: LCR, the ligase chain reaction, 2010. (Available from: http://www.chlamydiae.com, http://www.chlamydiae.com/restricted/docs/labtests/diag_lcr.asp [Accessed on June 2011]).
48. Batteiger BE, Xu F, Johnson RE, Rekart ML. Protective immunity to Chlamydia trachomatis genital infection: evidence from human studies. Journal of Infectious Diseases 2010; 202:S178-S189. DOI: 10.1086/652400.
49. Greenland S. Invited commentary: a critical look at some popular meta-analytic methods. American Journal of Epidemiology, AM 1994; 140:290-296.
50. Rubin DB. A new perspective. In The Future of Meta-analysis, Wachter KW, Straf ML (eds). Russell Sage Foundation: New York, 1990.
51. Ades AE, Lu G, Higgins JPT. The interpretation of random effects meta-analysis in decision models. Medical Decision Making 2005; 25:646-654. DOI: 10.1177/0272989X05282643.
52. Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. Journal of the Royal Statistical Society (A) 2009; 172:137-159. DOI: 10.1111/j.1467-985X.2008.00552.x.
53. Spiegelhalter DJ, Abrams KR, Myles J.Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Wiley: New York, 2004.
54. Turner RM, Spiegelhalter DJ, Smith GCS, Thompson SG. Bias modelling in evidence synthesis. Journal of the Royal Statistical Society (A) 2009; 172:21-47. [Online]. available at 10.1111/j.1467-985X.2008.00547.x.